Drug Profile
RB 92816
Latest Information Update: 18 Feb 2000
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 18 Feb 2000 No-Development-Reported for Cancer in USA (Unknown route)
- 19 Mar 1997 New profile
- 18 Mar 1997 Preclinical development for Cancer in USA (Unknown route)